Antioxidant Supplement
DrugAn antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
NCT Number: NCT02421887
The objective of the Males, Antioxidants, and Infertility (MOXI) Trial is to examine whether treatment of infertile males with an antioxidant formulation improves male fertility. The central hypothesis is that treatment of infertile males with antioxidants will improve sperm structure and function, resulting in higher fertilization rates and improved embryo development, leading to higher pregnancy and live birth rates. Findings from this research will be significant in that they will likely lead to an effective, non-hormonal treatment modality for male infertility. An effective treatment for men would also reduce the treatment burden on the female partner, lower costs, and provide effective alternatives to couples with religious or ethical contraindications to ART (Assisted Reproductive Technology). If antioxidants do not improve pregnancy rates, but do improve sperm motility and DNA integrity, they could allow for couples with male factor infertility to use less intensive therapies such as intrauterine insemination. Male fertility specialists currently prescribe antioxidants based on the limited data supporting their use. A negative finding, lack of any benefit, would also alter current treatment of infertile males.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Phase 2
Keck School of Medicine of University of Southern California, Los Angeles, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Couple
Male:
Female:
Exclusion criteria
Male:
Female:
An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
Placebo
Time frame: up to 15 months
Time frame: up to 7 months
Time frame: up to 9 months
miscarriages per total number of pregnancies
Time frame: up to 7 months
Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as a human Chorionic Gonadotropin (hCG) value over 5 on 2 separate occasions.
Time frame: baseline and 3 months
Samples will be assessed using a standard semen analysis
Time frame: Baseline and 3 months
DFI is the ratio of damaged sperm to total sperm. It is measured using Sperm Chromatin Structure Analysis (SCSA) which was performed on 5000 sperm per sample.
Time frame: baseline and 3 months
Samples assessed using a standard semen analysis
Time frame: baseline and 3 months
Samples assessed using a standard semen analysis
Time frame: baseline and 3 months
Samples assessed using a standard semen analysis
Time frame: baseline and 3 months
Samples assessed using a standard semen analysis
Yale University
Other
Males, Antioxidants, and Infertility (MOXI) Trial
Acronym: MOXI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07669402
Genital Diseases, Genital Diseases, Male
Tehran, Iran
View Trial DetailsNCT02006446
Aneuploidy, Chromosome Aberrations
Lille, France
View Trial DetailsNCT01407484
Cytopenia, Genital Diseases
Paris, France
View Trial DetailsNCT05503862
Genital Diseases, Genital Diseases, Male
Chicago, Illinois, United States
View Trial Details